Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Business Wire11-21

ROOT, Switzerland, November 21, 2024--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485991460?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/02sbtXW.cjB9K.GWQM6.1g--~B/aD00MDc7dz0yNzg1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a9010225a6e0e79ef0055ec55984450d","is_english":true,"pubTime":"2024-11-21 20:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2485991460","market":"us","top_or_hot":-1,"title":"Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma","media":"Business Wire","content":"<div>\n<p>ROOT, Switzerland, November 21, 2024--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novocure-data-2024-sno-annual-120500827.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novocure-data-2024-sno-annual-120500827.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ROOT, Switzerland, November 21, 2024--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novocure-data-2024-sno-annual-120500827.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://finance.yahoo.com/news/novocure-data-2024-sno-annual-120500827.html","article_id":"2485991460","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/02sbtXW.cjB9K.GWQM6.1g--~B/aD00MDc7dz0yNzg1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a9010225a6e0e79ef0055ec55984450d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485991460","pubTimestamp":1732190700,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"ROOT, Switzerland, November 21, 2024----Novocure  announced today that it will present new data for its Tumor Treating Fields  therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology , November 21 – 24, Houston, Texas.Novocure will present the results of its work to design arrays that will allow efficient and stable delivery of TTFields in mouse studies as well as research identifying the optimal positioning of its newly approved Head Flexible Electrodes  transducer arrays for infratentorial brain tumors. Novocure will also present a new subgroup analysis of patients from the xCures real-world data platform that assesses the results of treatment with TTFields in people with isocitrate dehydrogenase -mutant glioblastoma.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","NVCR":"NovoCure Limited","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓"},"translate_title":"Novocure在2024年SNO年会上的数据强调了胶质母细胞瘤肿瘤治疗场(TTFields)疗法的产品创新和真实世界证据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":1},"content_text":"ROOT, Switzerland, November 21, 2024--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 21 – 24, Houston, Texas.\nNovocure will present the results of its work to design arrays that will allow efficient and stable delivery of TTFields in mouse studies as well as research identifying the optimal positioning of its newly approved Head Flexible Electrodes (HFE) transducer arrays for infratentorial brain tumors. Novocure will also present a new subgroup analysis of patients from the xCures real-world data platform that assesses the results of treatment with TTFields in people with isocitrate dehydrogenase (IDH)-mutant glioblastoma.\nNovocure’s SNO 2024 Data Presentation Details\nOral Presentation (Abstract #TMOD-09): Newly designed Tumor Treating Fields (TTFields) arrays for the mouse head demonstrate efficacy for treatment of glioblastomaPresenting Author: Moshe Giladi, Novocure Ltd, Haifa, IsraelDate/Time: Sunday, November 24; 8:30 –10:00 a.m. CST\nPoster INNV-14: Outcomes of patients with isocitrate dehydrogenase-mutant WHO Grade 4 astrocytoma treated with Tumor Treating Fields (TTFields) therapy: a real-world analysisPresenting Author: Jennifer M. Connelly, Department of Neurology, Medical College of Wisconsin, Milwaukee, WIDate/Time: Friday, November 22; 7:30 – 9:30 p.m. CST\nPoster INNV-11: Delivery of TTFields to the infratentorial brain using HFE arraysPresenting Author: Dheeraj Bhavanasi, NovocureDate/Time: Friday, November 22; 7:30 – 9:30 p.m. CST\nIn addition, more than 20 independent preclinical, translational, real-world evidence and clinical studies of TTFields will be presented at the 2024 SNO Annual Meeting. Abstracts can be viewed here: https://academic.oup.com/neuro-oncology/issue/26/Supplement_8\nNovocure will also host a sponsored symposium, From Evidence to Practice: Impact of TTFields Therapy on Patient Outcomes, which will be held Friday, November 22, 12:45 –1:45 p.m. CST in Meeting Room: 351 (Level 3 at the George R. Brown Convention Center).\nAbout Tumor Treating Fields\nTumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors.\nTo learn more about TTFields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com.\nAbout Novocure\nNovocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.\nNovocure’s global headquarters is located in Root Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and X (Twitter).\nForward-Looking Statements\nIn addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as \"could\" \"anticipate,\" \"estimate,\" \"expect,\" \"project,\" \"intend,\" \"plan,\" \"believe\" or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241121815294/en/\nContacts\nInvestors: Ingrid Goldberg investorinfo@novocure.com\nMedia: Catherine Falcetti media@novocure.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485991460"}